These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 35866910)

  • 1. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
    Masuda K; Delozier AM; Kolodsick J; Buchanan A; Pink AE; Sun L; Wang Z; Stingeni L; Thac I D
    Eur J Dermatol; 2022 Apr; 32(2):237-243. PubMed ID: 35866910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
    Lio PA; Simpson EL; Han G; Soung J; Ball S; Sun L; Casillas M; DeLozier AM; Ding Y; Eichenfield LF
    J Dermatolog Treat; 2022 Jun; 33(4):2057-2062. PubMed ID: 34176407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
    Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
    J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
    Silverberg JI; Simpson EL; Thyssen JP; Werfel T; Cardillo TE; Colvin S; Pierce E; Chen YF; Chen S; Eichenfield L
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1036-1045. PubMed ID: 36514996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
    Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
    J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
    JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
    Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
    Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D; Fretzin S; Strowd L; Casillas M; DeLozier AM; Dawson Z; Chen S; Lu N; Thyssen JP
    J Cutan Med Surg; 2022; 26(4):377-385. PubMed ID: 35354410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
    Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
    JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
    Simpson EL; Lacour JP; Spelman L; Galimberti R; Eichenfield LF; Bissonnette R; King BA; Thyssen JP; Silverberg JI; Bieber T; Kabashima K; Tsunemi Y; Costanzo A; Guttman-Yassky E; Beck LA; Janes JM; DeLozier AM; Gamalo M; Brinker DR; Cardillo T; Nunes FP; Paller AS; Wollenberg A; Reich K
    Br J Dermatol; 2020 Aug; 183(2):242-255. PubMed ID: 31995838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
    Buhl T; Rosmarin D; Serra-Baldrich E; Fernandez-Peñas P; Igarashi A; Konstantinou MP; Chen S; Lu N; Pierce E; Casillas M
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):971-982. PubMed ID: 33899152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
    Bieber T; Thyssen JP; Irvine AD; Tsunemi Y; Chen YF; Sun L; Schloebe A; Riedl E; Cork MJ
    Clin Exp Dermatol; 2023 Jul; 48(8):881-888. PubMed ID: 37032446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.